HAVANA Cuban state biotech company Labiofam announced Monday in Havana that it has completed research and will soon being marketing the medication Vidatox, a therapy for treating cancer based on the properties of scorpion venom.
Scientists have found that the toxin in the venom of the Rophalorus junceus scorpion, endemic to Cuba, has an analgesic, anti-inflammatory and anticarcinogenic effect, Labiofam director Pavel Pizart and chief researcher Isbel Gonzalez said.
For more than 15 years the company has been doing research to discover the effectiveness of a treatment against tumors that uses scorpion venom.
By the end of the year, Labiofam expects to market a million doses of Vidatox in its homeopathic version, to be taken in sublingual drops, and is preparing another formula of the medication in a natural form without additives that patients will take orally.
Gonzalez said that during clinical trials more than 10,000 cancer patients took the treatment, including 3,500 foreigners, with positive results, above all in improving their quality of life and in stopping tumor growth.
The treatment has been administered to patients with cancer of the uterus, prostate, pancreas and lungs, among others.
The toxin is extracted from the scorpion by means of electric stimulus and each of these creatures can provide 0.02 milliliters of venom, equivalent to two or three drops.
At present there are 13 breeding facilities for scorpions in Cuba with an average of 5,000 of these arthropods each. EFE